A Study of HS-20110 in Participants With Advanced Solid Tumors
ConditionSolid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorHansoh BioMedical R&D Company
About this trial
This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors
Eligibility criteria
Qualifiers
Males or females, aged ≥ 18 years.
Participants with pathologically (histologically or cytologically) confirmed advanced solid tumors.
Participants have at least 1 target lesion other than CNS lesions according to RECIST 1.1.
Disqualifiers
Drug therapy targeting CDH17 (such as small molecule targeted drugs, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, or chimeric antigen receptor T cells).
Anti-tumor drugs within 14 days prior to the first dose of study treatment; any other IMPs or macromolecular anti-tumor drugs within 28 days prior to the first dose of study treatment.
Local radiotherapy within 2 weeks prior to the first dose of study treatment; irradiation of more than 30% of bone marrow or extensive radiotherapy within 4 weeks prior to the first dose of study treatment.
Major surgery within 4 weeks prior to the first dose of study treatment.
Trial design
Treatments tested in this trial
- HS-20110 (Phase Ia：Dose escalation )
- HS-20110 (Phase Ib:Dose expansion )
Treatment groups
475 Participants
are divided into 2 treatment groupsSponsors and collaborators
Hansoh BioMedical R&D Company
Lead sponsor
Hoffmann-La Roche
Collaborator
Source ClinicalTrials.gov